Cargando…

Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates

In this review, we have attempted to describe all of the antibody–drug conjugates using a marine-derived compound as the “warhead”, that are currently in clinical trials as listed in the current version of the NIH clinical trials database (clinicaltrials.gov). In searching this database, we used the...

Descripción completa

Detalles Bibliográficos
Autores principales: Newman, David J., Cragg, Gordon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408245/
https://www.ncbi.nlm.nih.gov/pubmed/28353637
http://dx.doi.org/10.3390/md15040099
_version_ 1783232269614317568
author Newman, David J.
Cragg, Gordon M.
author_facet Newman, David J.
Cragg, Gordon M.
author_sort Newman, David J.
collection PubMed
description In this review, we have attempted to describe all of the antibody–drug conjugates using a marine-derived compound as the “warhead”, that are currently in clinical trials as listed in the current version of the NIH clinical trials database (clinicaltrials.gov). In searching this database, we used the beta-test version currently available, as it permitted more specific search parameters, since the regular version did not always find trials that had been completed in the past with some agents. We also added small discussion sections on candidates that are still at the preclinical stage, including a derivative of diazonamide that has an unusual interaction with tubulin (DZ-23840), which may also be a potential warhead in the future.
format Online
Article
Text
id pubmed-5408245
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54082452017-05-03 Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates Newman, David J. Cragg, Gordon M. Mar Drugs Review In this review, we have attempted to describe all of the antibody–drug conjugates using a marine-derived compound as the “warhead”, that are currently in clinical trials as listed in the current version of the NIH clinical trials database (clinicaltrials.gov). In searching this database, we used the beta-test version currently available, as it permitted more specific search parameters, since the regular version did not always find trials that had been completed in the past with some agents. We also added small discussion sections on candidates that are still at the preclinical stage, including a derivative of diazonamide that has an unusual interaction with tubulin (DZ-23840), which may also be a potential warhead in the future. MDPI 2017-03-29 /pmc/articles/PMC5408245/ /pubmed/28353637 http://dx.doi.org/10.3390/md15040099 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Newman, David J.
Cragg, Gordon M.
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
title Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
title_full Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
title_fullStr Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
title_full_unstemmed Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
title_short Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
title_sort current status of marine-derived compounds as warheads in anti-tumor drug candidates
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408245/
https://www.ncbi.nlm.nih.gov/pubmed/28353637
http://dx.doi.org/10.3390/md15040099
work_keys_str_mv AT newmandavidj currentstatusofmarinederivedcompoundsaswarheadsinantitumordrugcandidates
AT cragggordonm currentstatusofmarinederivedcompoundsaswarheadsinantitumordrugcandidates